GYNECOLOGIC CANCERS

BioInvent's BI-1808 combined with pembrolizumab shows promising antitumor activity in recurrent ovarian cancer, offering hope for better treatment options.

The LARA trial reveals promising results for pembrolizumab and lenvatinib in treating recurrent clear cell gynecological cancer, showcasing effective antitumor activity.

The COLIBRI study reveals that neoadjuvant dual immune checkpoint blockade enhances treatment outcomes for locally advanced cervical cancer, showing promising immune responses.

Precision medicine revolutionizes endometrial cancer treatment, emphasizing molecular drivers and the challenges of next-generation sequencing in clinical decision-making.

Nutritional status significantly impacts survival and treatment outcomes in cervical cancer patients, highlighting the need for routine nutritional screening.

Researchers explore a promising nonchemotherapy treatment for low-grade serous ovarian cancer, combining ribociclib and letrozole to improve patient outcomes.

The ROSELLA trial reveals relacorilant plus nab-paclitaxel significantly improves survival in platinum-resistant ovarian cancer without increasing safety risks.

New cancer vaccine MVP-S shows promising results in recurrent ovarian cancer, enhancing immune response and improving treatment outcomes with pembrolizumab.

A groundbreaking trial reveals the promising efficacy of fruquintinib and sintilimab for advanced endometrial cancer, offering new hope for patients.

Sofetabart mipitecan receives FDA breakthrough therapy designation, showing promising efficacy in treating platinum-resistant ovarian cancer.

The SCORES trial reveals suvemcitug significantly enhances survival and disease control in patients with platinum-resistant recurrent ovarian cancer.

A systematic review reveals PARP inhibitors improve progression-free survival in advanced ovarian cancer but lack overall survival benefits, highlighting treatment variability.

Novel small molecule inhibitors show promising efficacy in endometrial cancer, with ongoing trials expanding treatment options for challenging patient populations.

ETX-19477 receives FDA fast track designation, promising accelerated development for treating BRCA-mutated, platinum-resistant ovarian cancer patients.

A novel antibody combination shows promising results in treating recurrent ovarian cancer, offering hope for better immunotherapy options.

A phase 2 trial shows ribociclib and letrozole effectively treat recurrent low-grade serous carcinoma, achieving significant response rates and durable control.

Discover groundbreaking advancements in gynecologic oncology, offering new hope for patients with challenging cancers through innovative therapies and clinical trials.

AstraZeneca and Daiichi Sankyo launch a pivotal trial to assess T-DXd as a potential adjuvant therapy for HER2-expressing endometrial cancer.

JSKN003, a novel HER2-targeting ADC, shows promising efficacy in treating platinum-resistant ovarian cancer, earning FDA breakthrough therapy designation.

A recent study reveals high rates of metastatic recurrence in adolescent and young adult cancer patients, emphasizing the need for tailored survivorship care.

Ipatasertib shows promising efficacy in heavily pretreated patients with AKT1E17K mutations, highlighting its potential in diverse tumor types.

New research reveals that high CD8-positive T-cell infiltration worsens outcomes for ovarian cancer patients treated with bevacizumab, challenging existing prognostic models.

The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient outcomes with targeted therapies.

Recent findings from the MIRASOL trial reveal significant advancements in treatment options for platinum-resistant ovarian cancer, emphasizing effective therapy sequencing.

New findings reveal that adding sapanisertib to weekly paclitaxel significantly improves progression-free survival in advanced ovarian cancer patients.